AbbVie has raised its 2027 sales forecast for its immunology drugs Skyrizi and Rinvoq to $27 billion, up $6 billion from its previous forecast. The Chicago-based drugmaker is counting on revenue from its new immunology drugs to help offset declining sales of its popular arthritis drug Humira.